PADCEV (enfortumab vedotin-ejfv) for injection

Quantity

Get it to United States within 10 working days with standard delivery.

Fast delivery to United States

Easy Returns & Exchanges

Ask About This Product

Condition : New

0

From UAE

To United States

in 5-10 days

Description

How It Works

PADCEV works by targeting a protein called Nectin-4, which is highly expressed in urothelial cancers. Enfortumab vedotin, the active ingredient in PADCEV, binds to Nectin-4 and delivers a potent chemotherapy drug directly to cancer cells. This targeted approach helps to kill cancer cells while minimizing damage to healthy tissues.

Side Effects

  • Fatigue
  • Nausea
  • Decreased appetite
  • Diarrhea
  • Peripheral neuropathy (numbness or tingling in the hands or feet)
  • Increased blood sugar levels

Indications

  • PADCEV is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.

Contraindications

  • Hypersensitivity to enfortumab vedotin-ejfv or any of the excipients
  • Severe renal impairment (creatinine clearance less than 30 mL/min)
  • Pregnancy or breastfeeding

Price Comparison in Different Countries

Country Price (USD) Reference
United States $17,000.00 GoodRx
United Kingdom ?14,000.00 NHS UK
Australia $20,000.00 AUD Pharmaceutical Benefits Scheme Australia
Canada $18,000.00 CAD MedBroadcast Canada

Top 5 Global Brands

  1. Astellas Pharma
  2. Pfizer
  3. Roche
  4. Bristol Myers Squibb
  5. Merck & Co.
 
Shopping Cart